combined anti-GD2 therapy with anti-CD47 therapy, which upregulated calreticulin expression on the surface of osteosarcoma cells, respectively, as well as promoting phagocytosis of osteosarcoma cells by macrophages (76). This evidence concerns the gene CALR and osteosarcoma.